Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636297 | 1.00 | PTGS2 (0.34) | PTGS2PTGS1 | |
| SCHEMBL3236736 | 0.90 | PTGS1 (0.32) | PTGS2PTGS1 | |
| SCHEMBL18115163 | 0.88 | CA1 (0.33) | PTGS2PTGS1 | |
| SCHEMBL12754381 | 0.86 | EPHX2 (0.30) | — | |
| SCHEMBL10104151 | 0.86 | EPHX2 (0.30) | — | |
| SCHEMBL13863668 | 0.84 | TSHR (0.41) | PTGS2PTGS1 | |
| SCHEMBL3238990 | 0.83 | PTGS2 (0.33) | PTGS2PTGS1 | |
| SCHEMBL21682522 | 0.82 | MAPT (0.40) | PTGS2PTGS1 | |
| SCHEMBL3232042 | 0.80 | PTGS1 (0.30) | PTGS2PTGS1 | |
| SCHEMBL397512 | 0.80 | EPHX2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2238143-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| EP-2326652-A1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2313417-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010014516-A1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| WO-2009150007-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | PTGS2 428/4885PTGS1 656/4885 |
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | PTGS2 1871/4885PTGS1 1395/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | PTGS2 105/4885PTGS1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.